| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/20000 | Human,Mouse,Rat |
| Aliases | LDLRAD2; Low-density lipoprotein receptor class A domain-containing protein 2 |
| Entrez GeneID | 401944; |
| WB Predicted band size | 29kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthesized peptide derived from the Internal region of human LDLRAD2. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.5%BSA and 50% glycerol. |
+ +
以下是关于LDLRAD2抗体的3篇参考文献示例(内容基于公开文献概括，部分信息为模拟虚构，实际文献需通过数据库核实)：
---
1. **文献名称**: *"LDLRAD2 as a novel mediator of dengue virus entry in human cells"*
**作者**: Smith A, et al.
**摘要**: 本研究通过CRISPR筛选发现LDLRAD2蛋白是登革热病毒入侵宿主细胞的关键受体。利用特异性抗体阻断LDLRAD2可显著抑制病毒感染，提示其作为潜在抗病毒靶点。
2. **文献名称**: *"Expression profiling of LDLRAD2 in colorectal cancer using a novel monoclonal antibody"*
**作者**: Chen L, et al.
**摘要**: 作者开发了一种高特异性抗LDLRAD2单克隆抗体，并用于结直肠癌组织分析。结果显示LDLRAD2在肿瘤组织中高表达，且与患者预后不良相关。
3. **文献名称**: *"LDLRAD2 regulates cholesterol metabolism through LDL receptor interaction"*
**作者**: Gupta R, et al.
**摘要**: 通过免疫共沉淀(使用抗LDLRAD2抗体)发现LDLRAD2与低密度脂蛋白受体(LDLR)相互作用，调控胆固醇内吞途径，为代谢疾病治疗提供新方向。
---
**备注**：以上文献为示例，实际研究中关于LDLRAD2抗体的直接文献较少，建议通过PubMed或Google Scholar结合关键词“LDLRAD2 antibody”或“LDLRAD2 function”检索最新研究。如需具体文献，可提供更详细的研究方向或应用场景。
The LDLRAD2 (Low-Density Lipoprotein Receptor Class A Domain-Containing 2) antibody is a tool used to study the LDLRAD2 protein, a member of the LDL receptor family. LDLRAD2 is characterized by its class A repeats, which mediate ligand binding and cellular interactions. While its precise biological role remains under investigation, LDLRAD2 is implicated in cell adhesion, signaling, and lipid metabolism regulation. It is expressed in various tissues, with emerging relevance in cancer and neurological disorders. Studies suggest LDLRAD2 may influence tumor progression by modulating pathways like Wnt/β-catenin, and its dysregulation has been observed in gliomas and colorectal cancers.
The LDLRAD2 antibody, typically generated using recombinant protein fragments or peptide immunogens, enables detection and localization of the protein via techniques such as Western blotting, immunohistochemistry, and immunofluorescence. Validation often includes knockout controls to confirm specificity. Research applications focus on elucidating LDLRAD2's role in disease mechanisms, particularly its involvement in metastasis, angiogenesis, and neural development. Commercial availability of this antibody supports both basic and translational studies, aiding efforts to explore LDLRAD2 as a potential biomarker or therapeutic target. Further investigation is needed to fully define its functional pathways and clinical significance.
×
